AU2022214463A1 - Methods for treating and ameliorating cancer - Google Patents

Methods for treating and ameliorating cancer Download PDF

Info

Publication number
AU2022214463A1
AU2022214463A1 AU2022214463A AU2022214463A AU2022214463A1 AU 2022214463 A1 AU2022214463 A1 AU 2022214463A1 AU 2022214463 A AU2022214463 A AU 2022214463A AU 2022214463 A AU2022214463 A AU 2022214463A AU 2022214463 A1 AU2022214463 A1 AU 2022214463A1
Authority
AU
Australia
Prior art keywords
optionally
aml
formulation
leukemia
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022214463A
Other languages
English (en)
Inventor
Larisa Balaian
Michael Burkart
Warren C. Chan
Leslie CREWS ROBERTSON
Raymond H. DIEP
Catriona Jamieson
James LACLAIR
Wenxue MA
Cayla MASON
Phoebe MONDALA
Inge VAN DER WERF
Peggy Wentworth
Thomas WHISENANT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2022214463A1 publication Critical patent/AU2022214463A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022214463A 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer Pending AU2022214463A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144378P 2021-02-01 2021-02-01
US63/144,378 2021-02-01
PCT/US2022/014663 WO2022165398A1 (en) 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer

Publications (1)

Publication Number Publication Date
AU2022214463A1 true AU2022214463A1 (en) 2023-09-14

Family

ID=82654982

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022214463A Pending AU2022214463A1 (en) 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer

Country Status (7)

Country Link
US (1) US20240148688A1 (https=)
EP (1) EP4284519A4 (https=)
JP (2) JP2024506847A (https=)
CN (1) CN116829142A (https=)
AU (1) AU2022214463A1 (https=)
CA (1) CA3206959A1 (https=)
WO (1) WO2022165398A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254465A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
WO2006044986A1 (en) 2004-10-18 2006-04-27 Nitto Denko Corporation Intracellular peptide delivery
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
WO2017053887A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Methods for detection and eradication of myeloid leukemia stem cells
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
WO2022159760A1 (en) * 2021-01-22 2022-07-28 The Regents Of The University Of California Methods for treating and ameliorating cancer

Also Published As

Publication number Publication date
EP4284519A1 (en) 2023-12-06
WO2022165398A1 (en) 2022-08-04
US20240148688A1 (en) 2024-05-09
JP2024506847A (ja) 2024-02-15
EP4284519A4 (en) 2024-12-25
CA3206959A1 (en) 2022-08-04
JP2025065209A (ja) 2025-04-17
CN116829142A (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
JP6974369B2 (ja) コエンザイムｑ１０併用療法を用いた癌の処置方法
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
JP4926256B2 (ja) 併用薬剤を送達するための組成物
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
KR101085203B1 (ko) 의약 전달용 인지질 나노입자
JP2019116517A (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
Salzano et al. Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
CN102427814A (zh) 激酶蛋白结合抑制剂
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
JP2025065209A (ja) がんを処置および改善するための方法
CN108883068B (zh) 乳癌治疗
Mattern-Schain et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics
KR102569052B1 (ko) 암의 치료를 위한 약제학적 조합물
US20240108734A1 (en) Methods for treating and ameliorating cancer
WO2013022827A1 (en) Method of treating acute myelogenous leukemia
US11583509B2 (en) Compound for treating cancer and diabetes
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
ES2809460T3 (es) Nuevo método de producción de lipoplejo para administración local y fármaco antitumoral que utiliza lipoplejo
CN102215833B (zh) 苯醌衍生物e3330联合化疗剂用于治疗癌症和血管生成
Zhu et al. Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy
US20250352490A1 (en) P-selectin targeted nanoparticles and uses thereof